Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ronen Arbel

Showing results (51-60 of 60) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 60 results.
European Journal of Preventive Cardiology|March 4, 2026
Machine learning to risk stratify individuals for undiagnosed atrial fibrillation at scale using population-wide electronic health recordsLior Rokach, Talish Razi Benita, Ramesh Nadarajah, et al.
Open Heart|July 10, 2023
Incident cardiovascular, renal, metabolic diseases and death in individuals identified for risk-guided atrial fibrillation screening: a nationwide cohort studyJianhua Wu, Ramesh Nadarajah, Yoko M Nakao, et al.
American Heart Journal|March 8, 2024
Risk calculator for incident atrial fibrillation across a range of prediction horizonsJianhua Wu, Ramesh Nadarajah, Yoko M Nakao, et al.
Heart (British Cardiac Society)|February 9, 2023
Prediction of short-term atrial fibrillation risk using primary care electronic health recordsRamesh Nadarajah, Jianhua Wu, David Hogg, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|June 28, 2024
Effectiveness and safety of molnupiravir in the intended-use population: an observational cohort studyWiessam Abu Ahmad, Ronen Arbel, Yael Wolff Sagy, et al.
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|July 22, 2022
Aspirin with Low-Dose Ticagrelor or with Low-Dose Rivaroxaban for Secondary Prevention: A Cost per Outcome AnalysisGal Tsaban, Hilmi Alnsasra, Aref El Nasasra, et al.
The New England Journal of Medicine|August 24, 2022
Nirmatrelvir Use and Severe Covid-19 Outcomes during the Omicron SurgeRonen Arbel, Yael Wolff Sagy, Moshe Hoshen, et al.
European Journal of Heart Failure|July 5, 2023
Prediction models for heart failure in the community: A systematic review and meta-analysisRamesh Nadarajah, Tanina Younsi, Elizabeth Romer, et al.
Nature Medicine|January 31, 2023
Real-world effectiveness of a single dose of mpox vaccine in malesYael Wolff Sagy, Roy Zucker, Ariel Hammerman, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|April 27, 2023
Risk assessment of human mpox infections: retrospective cohort studyRoy Zucker, Gil Lavie, Yael Wolff-Sagy, et al.
Pageof 6

Showing results (51-60 of 60) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 60 results.
European Journal of Preventive Cardiology|March 4, 2026
Machine learning to risk stratify individuals for undiagnosed atrial fibrillation at scale using population-wide electronic health recordsLior Rokach, Talish Razi Benita, Ramesh Nadarajah, et al.
Open Heart|July 10, 2023
Incident cardiovascular, renal, metabolic diseases and death in individuals identified for risk-guided atrial fibrillation screening: a nationwide cohort studyJianhua Wu, Ramesh Nadarajah, Yoko M Nakao, et al.
American Heart Journal|March 8, 2024
Risk calculator for incident atrial fibrillation across a range of prediction horizonsJianhua Wu, Ramesh Nadarajah, Yoko M Nakao, et al.
Heart (British Cardiac Society)|February 9, 2023
Prediction of short-term atrial fibrillation risk using primary care electronic health recordsRamesh Nadarajah, Jianhua Wu, David Hogg, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|June 28, 2024
Effectiveness and safety of molnupiravir in the intended-use population: an observational cohort studyWiessam Abu Ahmad, Ronen Arbel, Yael Wolff Sagy, et al.
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|July 22, 2022
Aspirin with Low-Dose Ticagrelor or with Low-Dose Rivaroxaban for Secondary Prevention: A Cost per Outcome AnalysisGal Tsaban, Hilmi Alnsasra, Aref El Nasasra, et al.
The New England Journal of Medicine|August 24, 2022
Nirmatrelvir Use and Severe Covid-19 Outcomes during the Omicron SurgeRonen Arbel, Yael Wolff Sagy, Moshe Hoshen, et al.
European Journal of Heart Failure|July 5, 2023
Prediction models for heart failure in the community: A systematic review and meta-analysisRamesh Nadarajah, Tanina Younsi, Elizabeth Romer, et al.
Nature Medicine|January 31, 2023
Real-world effectiveness of a single dose of mpox vaccine in malesYael Wolff Sagy, Roy Zucker, Ariel Hammerman, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|April 27, 2023
Risk assessment of human mpox infections: retrospective cohort studyRoy Zucker, Gil Lavie, Yael Wolff-Sagy, et al.
Pageof 6